RecruitingPhase 2NCT06976619

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes

The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People

Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Oct 3, 2025

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes Type 2 Diabetes

Summary

The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.

Eligibility

Min Age: 25 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how blood sugar control and a class of diabetes medications called GLP-1 receptor agonists (such as semaglutide or liraglutide) affect the pancreas in people with diabetes. Researchers want to understand how these treatments change the way the pancreas produces certain hormones. **You may be eligible if...** - You have been diagnosed with type 1 or type 2 diabetes - You are currently treated with insulin - You are between 25 and 70 years old - Your HbA1c (a measure of average blood sugar) is 10.0% or below **You may NOT be eligible if...** - You have had certain upper abdominal surgeries, such as gastric banding or stomach surgery - You have used a GLP-1 receptor agonist medication in the past year - You have an active illness or active cancer - You have significant complications from diabetes affecting your heart or blood vessels - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.